

Robin Cornelissen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4449365/robin-cornelissen-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

424
citations

12
h-index

19
g-index

37
ext. papers

613
ext. citations

4.2
avg, IF

3.73
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 34 | Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study.. <i>Thorax</i> , 2022 , | 7.3 | 2 |
| 33 | Pozotinib in Non-Small-Cell Lung Cancer Harboring Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101323 | 2.2 | 11 |
| 32 | Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. <i>EBioMedicine</i> , 2021 , 64, 103160 | 8.8 | 5 |
| 31 | Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100155 | 1.4 | 2 |
| 30 | Genetic polymorphism in is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. <i>Thorax</i> , 2021 , 76, 1150-1153 | 7.3 | 1 |
| 29 | Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2618-2618 | 2.2 | |
| 28 | Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. <i>Vaccines</i> , 2021 , 9, | 5.3 | 3 |
| 27 | ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype. <i>Lung Cancer</i> , 2021 , 156, 72-75 | 5.9 | 1 |
| 26 | Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3329-3338 | 4.4 | 1 |
| 25 | High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2021 , 144, 41-48 | 7.5 | 26 |
| 24 | Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021 , 12, 880-889 | 3.2 | 13 |
| 23 | The psychosocial impact of living with mesothelioma: Experiences and needs of patients and their carers regarding supportive care. <i>European Journal of Cancer Care</i> , 2021 , 30, e13498 | 2.4 | 1 |
| 22 | Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1472-1483 | 8.9 | 10 |
| 21 | T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma 2020 , 8, | | 11 |
| 20 | Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer. <i>Radiation Oncology</i> , 2020 , 15, 89 | 4.2 | 2 |
| 19 | Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3074-3074 | 2.2 | 2 |
| 18 | Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma. <i>Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery</i> , 2020 , 2020, | 0.2 | |

| | | | |
|----|---|------|----|
| 17 | Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1169-1179 | 4.4 | 16 |
| 16 | Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis. <i>Frontiers in Oncology</i> , 2020 , 10, 577696 | 5.3 | 8 |
| 15 | ALK in Mesothelioma: To FISH or Not to FISH?. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e168-e169 | 8.9 | 1 |
| 14 | A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENDritic cell Immunotherapy for Mesothelioma (DENIM) trial. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1170-1179 | 4.4 | 27 |
| 13 | Endovascular Coils as Lung Tumor Fiducial Markers for Real-Time Tumor Tracking in Stereotactic Body Radiotherapy: Comparison of Complication Rates with Transthoracic Fiducial Marker Placement. <i>Journal of Vascular and Interventional Radiology</i> , 2019 , 30, 1901-1907 | 2.4 | 3 |
| 12 | Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. <i>Clinical Cancer Research</i> , 2018 , 24, 766-776 | 12.9 | 42 |
| 11 | Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. <i>Onc Immunology</i> , 2018 , 7, e1474318 | 7.2 | 16 |
| 10 | Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2018 , 19, | 6.3 | 39 |
| 9 | Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1317-1324 | 7.4 | 4 |
| 8 | Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. <i>Lung Cancer</i> , 2017 , 107, 36-40 | 5.9 | 12 |
| 7 | Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <i>Immunotherapy</i> , 2017 , 9, 507-520 | 3.8 | 8 |
| 6 | Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017 , 40, 511-519 | 7.2 | 4 |
| 5 | Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015 , 88, 332-7 | 5.9 | 17 |
| 4 | Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. <i>PLoS ONE</i> , 2014 , 9, e106742 | 3.7 | 69 |
| 3 | Dendritic cell-based immunotherapy in mesothelioma. <i>Immunotherapy</i> , 2012 , 4, 1011-22 | 3.8 | 8 |
| 2 | A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 398, 2943-8 | 4.4 | 24 |
| 1 | Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. <i>Radiation Oncology</i> , 2007 , 2, 2 | 4.2 | 26 |